Skip to content

ZEro Pacemaker Implantation Sutureless Aortic Valve Replacement Study

ZEro Pacemaker Implantation Sutureless Aortic Valve Replacement Study - ZEPIS-AVR Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1032230138
Enrollment
80
Registered
2023-06-16
Start date
2023-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic stenosis Aortic stenosis

Interventions

In this study, a new implantation protocol for aortic valve replacement using a sutureless bioprosthetic valve for aortic stenosis (or aortic stenosis and regurgitation) consisting of visual confirmat

Sponsors

Tabata Minoru
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients undergoing aortic valve replacement using the Perceval bioprosthetic valve for aortic stenosis or aortic stenosis cum regurgitation at institutions participating in this study will be eligible. Selection Criteria (1) Age 18 years or older at the time of consent (2) Patients with aortic valve disease that can be treated with the commercially available Perceval bioprosthetic valve as determined by preoperative CT scan or transesophageal echocardiography. 3) Patients who are judged to be suitable for Perceval bioprosthetic valve based on their age, general condition, and comorbidities. (iv) Patients who are eligible for 30-day postoperative follow-up (5) Patients who have received a thorough explanation of their participation in this study, and who have given their free and voluntary written consent based on a thorough understanding of the study.

Exclusion criteria

Exclusion criteria: Exclusion Criteria (1) Patients undergoing concomitant surgery other than coronary artery bypass surgery (2) Patients undergoing preoperative pacemaker (including implantable cardioverter defibrillator) implantation (3) Patients with a preoperative diagnosis of chronic atrial fibrillation or atrioventricular block of two or more degrees (4) Patients with a contraindication to Perceval bioprosthetic valve treatment in the package insert (5) Patients with congenital bicuspid aortic valve (Sievers type 0) or unicuspid aortic valve (6) Patients with aortic aneurysm or dissection of the ascending aorta (vii) Patients with active endocarditis, myocarditis, or sepsis (viii) If the subject is already participating in another clinical trial that may confound the results of this study (ix) Other cases in which the principal investigator determines that the subject is inappropriate as a research subject.

Design outcomes

Primary

MeasureTime frame
Implementation of permanent pacemaker implantation up to 30 days postoperatively (including reason, timing, and model of implantation)

Secondary

MeasureTime frame
1) New atrioventricular block (2nd or 3rd degree) and left bundle branch block at 30 days postoperatively 2) Intraoperative membranous septal injury 3) Re-implantation of prosthetic valve due to migration of the Scherless bioprosthetic valve 4) Periprosthetic regurgitation (zero, trivial, mild, moderate, severe) assessed by transthoracic echocardiogram before discharge

Contacts

Public ContactTakeshi Kinoshita

Juntendo University

t.kinoshita.pl@juntendo.ac.jp+81-3-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026